Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Michel Peterschmitt, Nigel P.S. Crawford, Sebastiaan J.M. Gaemers, et al.
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 1, pp. 86-98
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Function and therapeutic value of astrocytes in neurological diseases
Hong‐Gyun Lee, Michael A. Wheeler, Francisco J. Quintana
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 5, pp. 339-358
Open Access | Times Cited: 364
Cardiac Involvement in Fabry Disease
Maurizio Pieroni, James Moon, Eloisa Arbustini, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 7, pp. 922-936
Open Access | Times Cited: 211
Restrictive cardiomyopathy: definition and diagnosis
Claudio Rapezzi, Alberto Aimo, Andrea Barison, et al.
European Heart Journal (2022) Vol. 43, Iss. 45, pp. 4679-4693
Open Access | Times Cited: 103
Fabry Disease: The Current Treatment Landscape
Malte Lenders, Eva Brand
Drugs (2021) Vol. 81, Iss. 6, pp. 635-645
Open Access | Times Cited: 102
Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions
Ken Kok, Kimberley C. Zwiers, Rolf G. Boot, et al.
Biomolecules (2021) Vol. 11, Iss. 2, pp. 271-271
Open Access | Times Cited: 94
GM1 Gangliosidosis—A Mini-Review
Elena‐Raluca Nicoli, Ida Annunziata, Alessandra d’Azzo, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 69
The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches
Alice Drobny, Susy Prieto Huarcaya, Jan Philipp Dobert, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2022) Vol. 1869, Iss. 7, pp. 119243-119243
Open Access | Times Cited: 53
Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments
Matthew E. Gegg, Elisa Menozzi, Anthony H.V. Schapira
Neurobiology of Disease (2022) Vol. 166, pp. 105663-105663
Open Access | Times Cited: 48
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease
Shirley Yin-Yu Pang, Rachel Lo, Philip Wing‐Lok Ho, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 45
The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
Neal J. Weinreb, Özlem Göker-Alpan, Priya S. Kishnani, et al.
Molecular Genetics and Metabolism (2022) Vol. 136, Iss. 1, pp. 4-21
Open Access | Times Cited: 44
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Nir Giladi, Roy N. Alcalay, Gary Cutter, et al.
The Lancet Neurology (2023) Vol. 22, Iss. 8, pp. 661-671
Closed Access | Times Cited: 41
Regulation of Autophagy via Carbohydrate and Lipid Metabolism in Cancer
Javad Alizadeh, Mahboubeh Kavoosi, Navjit Singh, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2195-2195
Open Access | Times Cited: 37
New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Konstantin Senkevich, Uladzislau Rudakou, Ziv Gan‐Or
Neuropharmacology (2021) Vol. 202, pp. 108822-108822
Closed Access | Times Cited: 53
Therapeutic Approaches in Lysosomal Storage Diseases
Carlos Fernández-Pereira, Beatriz San Millán, María Gallardo‐Gómez, et al.
Biomolecules (2021) Vol. 11, Iss. 12, pp. 1775-1775
Open Access | Times Cited: 44
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial
Raphael Schiffmann, Timothy M. Cox, Jean-François Dedieu, et al.
Brain (2022) Vol. 146, Iss. 2, pp. 461-474
Open Access | Times Cited: 29
Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct
Alexandra Gehrlein, Vinod Udayar, Nadia Anastasi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Treatment of Fabry Disease: Established and Emerging Therapies
Muhammad Umer, Dinesh Kalra
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 320-320
Open Access | Times Cited: 19
Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies
David Baggett, Alex Olson, Mayur Parmar
Brain Disorders (2024), pp. 100163-100163
Open Access | Times Cited: 7
Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes
Emily Daykin, Emory Ryan, Ellen Sidransky
Molecular Genetics and Metabolism (2021) Vol. 132, Iss. 2, pp. 49-58
Open Access | Times Cited: 40
Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review
Lina Palaiodimou, Panagiotis Kokotis, Christina Zompola, et al.
Current Neuropharmacology (2022) Vol. 21, Iss. 3, pp. 440-456
Open Access | Times Cited: 26
Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome
Yang Liu, Hatim Thaker, Chunyan Wang, et al.
Toxins (2022) Vol. 15, Iss. 1, pp. 10-10
Open Access | Times Cited: 23
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments
Iacopo Olivotto, James E. Udelson, Maurizio Pieroni, et al.
European Heart Journal (2022) Vol. 44, Iss. 8, pp. 656-667
Open Access | Times Cited: 23
CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model
Sheng Cui, Yoo Jin Shin, Xianying Fang, et al.
Translational research (2023) Vol. 258, pp. 35-46
Closed Access | Times Cited: 13
Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies
Lijun Dai, Miao Liu, Ke Wei, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 5
Targeting the Sphingolipid Rheostat in Gliomas
Faris Zaibaq, Tyrone Dowdy, Mioara Larion
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9255-9255
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top